Dyne released promising new data on its Duchenne muscular dystrophy drug, DYNE-251, as well as its myotonic dystrophy type 1 treatment DYNE-101.
The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.
About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1
Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley’s salary is lower than Andrew Witty’s; Trump considers Medicare negotiation of drug prices
In our struggle with the bean counters and the stockbrokers, can’t we make patient needs a priority, too?
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to:
